| Ytd | -34.09% | |
| 1y | -73.75% |
| Open | Prev Close | 7.25 | Low | High | Mkt Cap | 49.17M | |||
| Vol | 0.00 | Avg Vol | 21.58K | EPS | -7.08 | P/E | -1.02 | Forward P/E | -1.80 |
| Beta | 1.90 | Short Ratio | 2.29 | Inst. Own | 80.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-04 | 50-d Avg | 7.84 | 200-d Avg | 10.15 | 1yr Est | 100.33 |
TIL News
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculati
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN C
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of stra
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that i
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to
Instil Bio, Inc. (NASDAQ: TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned sub
Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced
DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stag
During Thursday, 849 stocks hit new 52-week lows.